Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
|
|
- Thomasina Caldwell
- 5 years ago
- Views:
Transcription
1 Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine Baltimore, MD Disclosures Amarin: Consultant and Member, Steering Committee- REDUCE-IT trial. 1
2 Objectives Upon completion of this activity, participants will Evaluate the contribution of elevated triglycerides and non-hdl-c to residual CVD risk that remains even after LDL-cholesterol is well-controlled Describe the clinical trial evidence demonstrating CVD risk reduction using lipid-modifying therapies in patients with atherogenic dyslipidemia and determine which patients would benefit most from combination lipid-modifying therapies Triglycerides - Triacylglycerol Triglycerides are water-insoluble lipids consisting of three fatty acids linked to one glycerol molecule They represent a concentrated source of metabolic energy contributing 9 kcal/gm Citkowitz E, et al. Medscape article. Accessed August 1, Minami Nutrition website. Accessed August 1,
3 Overview of TG Metabolism Dietary Fat Adipose Tissue and Muscle GPIHBP1 Vascular Wall Macrophages E B-100 C-III IDL LPL, HGTL B-100 LPL Miller M, et al. Circulation. 2011;123: CIII B-48 C-II E Chylomicron LDL CII E VLDL B-100 C-III LPL LPL C-III C-III FFAs LDL-R LRP LRP B-100 VLDL B-48 CMR Apo A-V E E B-100 IDL, VLDL-R Metabolic Consequences of Hypertriglyceridemia Insulin Resistance FFA DGAT HDL TG/VLDL-C CETP Apo A-I CE TG HTGL Atherogenic Dyslipidemia HDL-C small-dense VLDL LDL particles VLDL ( LDL-C) TG TG TG TG TG Apo B-100 HDL Apo A-I Small, dense HDL Glycerol CE TG CETP CE HTGL LDL Apo B-100 Liver Miller M, et al. Circulation. 2011;123: Apo B-100 LDL TG Small, dense LDL 3
4 Mechanisms for Enhanced Atherogenesis of Small Dense LDL Mudd JO, et al. J Am Coll Cardiol. 2007;50(18): Cumulative Distribution of Adjusted Plasma TG Levels: LDL Phenotypes A and B Austin M, et al. Circulation. 1990;82:
5 Elevated Triglycerides Are Associated With Increased Small, Dense LDL Particles Fewer Particles More Particles Apo B LDL= 130 mg/dl More Apo B Cholesterol Ester Correlates with: TC 198 mg/dl LDL-C 130 mg/dl TG 90 mg/dl HDL-C 50 mg/dl Non HDL-C 148 mg/dl Correlates with: TC 210 mg/dl LDL-C 130 mg/dl TG 250 mg/dl HDL-C 30 mg/dl Non HDL-C 180 mg/dl Otvos JD, et al. Am J Cardiol. 2002;90:22i-29i. Epidemiology of High TG and CVD Risk 5
6 Designation of Triglyceride Cutpoints 1984 NIH Consensus 1993 NCEP Guidelines 2001 NCEP Guidelines 2011 AHA Statement Optimal <100 Desirable < 250 < 200 < 150 < 150 Borderline High Very High > 1000 > 1000 > 500 > 500 Prevalence of Elevated TG ( ) 20+ yrs >150 >200 > 500 Overall 31% 16% 1.1% Men 35% 20% 1.8% Women 27% 13% 0.5% Heritage Mexican 35% 20% 1.4% African 16% 8% 0.4% European 33% 18% 1.1% Miller M, et al. Circulation. 2011;123:
7 Secondary Causes of Hypertriglyceridemia Estrogen Tamoxifen Alcohol Coffee Hypothyroidism Diabetes Liver disease Nephrotic syndrome Pregnancy Obesity Lipodystrophy Gaucher s disease Glycogen storage disease type I Medications Thiazides Beta blockers Corticosteroids Retinoids Protease inhibitors Long-term interferon Antipsychotic meds Eruptive Xanthomas TG>1000:PE Findings Lipemia Retinalis 7
8 TG and CHD Risk: Meta-Analysis of 29 Studies Groups CHD Cases 10 years 5902 <10 years 4256 Sex Male 7728 Female 1994 Fasting Status Fasting 7484 Nonfasting 2674 Adjusted for HDL Yes 4469 No 5689 Decreased Risk CHD Risk Ratio* (95% CI) Overall CHD Risk Ratio* 1 Increased Risk 1.72 (95% CI, ) *Individuals in top versus bottom third of usual log-tg values, adjusted for at least age, sex, smoking status, lipid concentrations, and (in most studies) blood pressure. Sarwar N, et al. Circulation. 2007;115: N=262,525 Elevated Triglycerides Increase the Risk of CHD at All Levels of LDL-C Incidence of CHD Events According to Serum LDL-C and TG Concentration* CHD Cases / 1000 in 8 Years Baseline TG <200 mg/dl Baseline TG 200 mg/dl Baseline LDL-C (mg/dl) * Lipids from 4849 middle-aged men who were followed up for 8 years to record incidence of CHD. Study demonstrated that fasting levels of TGs were an independent risk factor for CHD events, irrespective of serum levels of LDL-C. The effect of POM3 on the risk of pancreatitis in patients with very high TG levels has not been evaluated. The effect of POM3 on cardiovascular mortality and morbidity in patients with very high TG levels has not been determined. CHD=coronary heart disease; LDL-C=low-density lipoprotein cholesterol; TG=triglyceride. Adapted from Assmann G, et al. Eur Heart J. 1998;19(suppl M):M8-M14. 8
9 Residual CVD Risk in Patients Treated With Statins 40 Residual CVD Risk in Statin vs Placebo Trials CHD Events Occur in Patients Treated with Statins Patients Experiencing Major CHD Events, % Placebo Statin S 1 LIPID 2 CARE 3 HPS 4 WOSCOPS 5 AFCAPS/TexCAPS 6 N LDL -35% -25% -28% -29% -26% -25% Secondary High Risk Primary 1 4S Group. Lancet. 1994;344: LIPID Study Group. N Engl J Med. 1998;339: Sacks FM et al. N Engl J Med. 1996;335: HPS Collaborative Group. Lancet. 2002;360: Shepherd J et al. N Engl J Med. 1995;333: Downs JR et al. JAMA. 1998;279:
10 Low HDL-C Increases CVD Risk Even If LDL-C Levels Are Well-Controlled Treating to New Targets (TNT) Study 5-Year Risk of Major CVD Events, % HDL-C Quintiles, a mg/dl Hazard Ratio Versus Q1* Patients With LDL-C 70 mg/dl on Statin a,b TG=186 TG=168 TG=150 TG=142 TG=124 Q1 <37 Q2 37 to <42 Q3 42 to <47 Q4 47 to <55 Q % Lower Risk a On-treatment level (3 months statin therapy); n = 2661 b Mean LDL-C, 58 mg/dl; mean TG, 126 mg/dl *P=.03 for differences among quintiles of HDL-C Barter P, et al. New Engl J Med. 2007;357: TG >150 mg/dl & CHD Events a In Patients With ACS on Statins b PROVE IT-TIMI 22 Trial N = 4162 LDL-C TG CHD Event a Rate, % HR: 0.81 (0.68, 0.96) P=.015 LDL-C 70 LDL-C <70 CHD Event a Rate, % HR: 0.73 (0.62, 0.87) P<.001 TG 150 TG < Days After Month 1 Visit ACS, acute coronary syndrome a Death, MI, and recurrent ACS b Atorvastatin 80 mg or pravastatin 40 mg Lipid values are in mg/dl Reprinted with permission from Miller M, et al. J Am Coll Cardiol. 2008;51: Days After Month 1 Visit Each 10 mg/dl in TG = 1.8% in CHD risk (P<.001) 10
11 TG < 150 mg/dl Associated With Lower Risk of CHD Events a Independent of LDL-C Level PROVE IT-TIMI 22 Trial b Achieving both low LDL-C and low TG (<150 mg/dl) may be important therapeutic strategies in patients after an ACS N = 4162 HR: 0.85 P=.180 Referent CHD Event a Rate After 30 Days c, % HR: 0.72 P=.017 HR: 0.84 P=.192 LDL-C 70 LDL-C <70 a Death, MI, and recurrent ACS TG <150 TG 150 b ACS patients on atorvastatin 80 mg or pravastatin 40 mg c Adjusted for age, gender, low HDL-C, smoking, hypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheral vascular disease, and treatment Lipid values are in mg/dl Reprinted with permission from Miller M, et al. J Am Coll Cardiol. 2008;51: Practical Algorithm for Screening and Management of Elevated Triglycerides Miller M, et al. Circulation. 2011;123:
12 Effects of Nutrition Practices on Triglyceride Lowering Nutrition Practice TG-Lowering Weight loss 20% (5% to 10% of body weight) Implement a Mediterranean-style diet 10 15% vs a low-fat diet Add marine-derived PUFA (EPA/DHA) (per gram) 5 10% Decrease carbohydrates 1% Energy replacement with MUFA/PUFA 1 2% Eliminate trans fats 1% Energy replacement with MUFA/PUFA 1% Miller M, et al. Circulation. 2011;123: Effect of Lipid-lowering Therapies on TG Reduction (%) Fibrates 30-50% Niacin 20-50% Omega % Statins 10-30% Ezetimibe 5-10% Clinical Lipidology: A Companion to Braunwald s Heart Disease (Ballantyne CM, ed) 2009;
13 Clinical Trial Evidence Supporting Treating Beyond LDL-C to Reduce CVD Risk Treating Beyond LDL-C: Niacin Therapy 13
14 AIM-HIGH Primary Endpoint: CHD Death, Nonfatal MI, Ischemic Stroke, High-risk ACS, Hospitalization for Coronary or Cerebrovascular Revascularization Baseline Lipid Levels (Monotherapy arm, n=1696) Lipid LDL-C 74.0 (22.7) Cumulative % with Primary Outcome AIM-HIGH Investigators. N Engl J Med. 2011;365: ; Guyton J, et al. JACC. Epub July 20, Combination Therapy Monotherapy Non-HDL-C (26.0) 30 HDL-C 34.9 (5.6) HR 1.02, 95% CI Log-rank P value= % TG % 10 TG 198 mg/dl + HDL-C<33 mg/dl 0 (tertiles) trend toward benefit. N at risk Time (years) Monotherapy (Statin) Combination Therapy (Statin + ERN) HPS2-THRIVE: Randomized Placebo-controlled Trial of ERN and Laropiprant in 25,673 Patients with Pre-existing CVD Baseline Lipids on Statin-based Rx Lipid Mean (SD),mg/dL Total cholesterol 128 (22) Direct-LDL 63 (17) HDL-C 44 (11) TG 125 (74) 5 Placebo ERN/LRPT Years of follow-up *Non-fatal MI or coronary death, any non-fatal or fatal stroke, coronary or non-coronary artery surgery or angioplasty. LRPT= laropiprant. Presented at: ACC.13: American College of Cardiology 62nd Annual Scientific Session. Available at: Patients Suffering Events (%) Effect of ERN/LRPT on Major Vascular Events* 20 Risk ratio 0.96 (95% CI ) Logrank P= % 15 Significant excesses of serious adverse events (SAEs) due to known and unrecognised side-effects of niacin. Over 4 years, ER niacin/laropiprant caused SAEs in ~30 patients per % 14
15 Treating Beyond LDL-C: Fibrate Therapy Meta-analysis of Randomized Trials of Fibrate Drugs Dyslipidemia: TG 204 mg/dl, HDL-C 34 mg/dl Complementary subgroups: TG < 204 mg/dl, HDL-C > 34 mg/dl Odds ratio 35% in dyslipidemia Sacks FM, et al. N Engl J Med. 2010;363(7):
16 Treating Beyond LDL-C: Omega-3 Fatty Acid Therapy OM-3 FA Molecular Structure PUFA=polyunsaturated FA. Adapted from Mozafarian D, Wu JH. J Am Coll Cardiol. 2011;58:
17 Japan EPA Lipid Intervention Study (JELIS) 18,645 subjects, primary and secondary prevention 4 Major CV Events (%) Statin Statin +EPA (1.8g/day) Hazard ratio = 0.81 ( ) p = % Years Adapted from Yokoyama M. Lancet. 2007;369: Clinical Outcome Studies Evaluating High TG Subgroups Trial (Drug) Primary Endpoint: Entire Cohort (P-value) Lipid Subgroup Criterion Primary Endpoint: Subgroup (P-value) Prestatin era HHS (Gemfibrozil) BIP (Bezafibrate) -34% (0.02) -9.4% (0.26) TG > 204 mg/dl LDL-C/HDL-C > 5.0 TG > 200 mg/dl HDL-C <35 mg/dl -71% (0.005) -42% (0.02) Some statin use FIELD (Fenofibrate) (no statins at entry) -11% (0.16) TG > 150 mg/dl -12% (0.07) Statin add-on ACCORD (Fenofibrate/simva) JELIS (ethyl EPA) (simva & prava) -8% (0.32) -19% (0.011) TG > 204 mg/dl HDL-C < 34 mg/dl TG > 150 mg/dl HDL-C < 40 mg/dl -31% (0.0567) -53% (0.043) 17
18 OM-3 Ethyl Esters and Lipid Levels in Patients with TG >500 mg/dl Baseline (mg/dl) TG 816 HDL-C 22 Non-HDL-C 27 TC 296 VLDL-C 175 LDL-C 89 60% P< Change in Median Levels 40% 20% 0% -20% -40% P< P= P= P= P< % Placebo OM-3 Acid Ethyl Esters (4 g/day) Pooled analysis (N=82). Harris WS et al. J Cardiovasc Risk 1997;4: and Pownall HJ et al. Atherosclerosis 1999;143: Median Placebo-adjusted Change (%) MARINE: Icosapent Ethyl (Pure EPA): Median Placebo-adjusted Change from Baseline for Efficacy Endpoints The MARINE Study: TG >500 mg/dl TG Non-HDL-C VLDL-C Lp-PLA 2 Apo B TC ǁ ǁ -8.1 * * NS NS ǁ -6.8 * LDL-C NS NS HDL-C NS NS Icosapent Ethyl 4 g/day (n=76) FDA approved dose 2 g/day (n=73) *P<0.05. P<0.01. P< ǁ P< NS = P P-values reflect differences between icosapent ethyl vs placebo. ITT Population VLDL-TG NS hscrp EPA=eicosapentaenoic acid; ITT=intention to treat; Lp-PLA=lipoprotein-associated phospholipase A; MARINE= Multi-center, Placebocontrolled, Randomized, Double-blind, 12-week Study with an Open-label Extension. Bays HE et al. Am J Cardiol. 2011;108: Bays HE et al. Paper presented at: European Society of Cardiology (ESC) Congress 2011; August 29, 2011; Paris, France NS 18
19 ANCHOR: Icosapent Ethyl (Pure EPA): Median Placebo-Adjusted Change from Baseline for Efficacy Endpoints The ANCHOR Study: TG 200 and <500 mg/dl Median Placebo-adjusted Change (%) TG Non-HDL-C Apo B LDL-C HDL-C Baseline values (mg/dl) ǁ ǁ ǁ -3.8 * NS NS *P<0.05. P<0.01. P< ǁ P< NS = P P-values reflect differences between icosapent ethyl vs placebo Note: EPA is not FDA approved for TG mg/dl 4 g/day (n=233) 2 g/day (n=236) 12-week trial in high-risk statin-treated patients (N=702) with residually TG levels ( 200 and <500 mg/dl) despite LDL-C control ( 40 and <100 mg/dl). ANCHOR= Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels ( 200 and < 500 mg/dl). Ballantyne CM et al. Am J Cardiol. 2012;110: Reduction of CV Events with EPA Intervention Trial Men & women 45 yo Prior CHD (70% patients) or T2DM + 1 RF) Atherogenic dyslipidemia: Hx of TC (at LDL-C goal on statin) TG mg/dl N=8000 AMR101, 4 g/day Placebo Primary endpoint: Prevention of 1 st major CV event Study duration ~4 6 yrs Randomized, double-blind, parallel group design Secondary outcome measures: Incidence of additional CV events, lipid and lipoprotein levels, subgroup analyses such as diabetes, etc. Multinational trial Anticipated completion 2016 AMR101=icosapent ethyl REDUCE-IT=Reduction of Cardiovascular Events with EPA -Intervention Trial. A Study of AMR101. NIH website. 19
20 New Drugs in Triglyceride Metabolism Variety of targets DGAT inhibition MTP inhibition Gene therapy Complex pathways, multiple candidates Efficacy (outcomes) and safety remain under investigation Summary Residual CVD risk is high in CHD & diabetic patients treated with statins, likely due to the atherogenic dyslipidemia characteristic of this patient population (elevated TG and low HDL-C) U.S. guidelines recommend that combination therapy may be necessary to achieve primary and secondary (LDL-C, non HDL-C) targets Combination therapy with statins and niacin/ fenofibrate/ fish oil corrects atherogenic lipid abnormalities, with the latter 2 therapies associated with reduced CV risk in subgroup analyses Ongoing clinical trial(s) will assess whether combination therapy is clinically superior to statin monotherapy in hypertg patients 20
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationSESSION 5 2:15pm 3:45pm
SESSION 5 2:15pm 3:45pm Current Perspectives and Emerging Approaches in Lipid Management SPEAKERS Michael Miller, MD, FACC, FAHA Michael Blaha, MD, MPH Presenter Disclosure Information The following relationships
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationAMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study
AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study HE Bays, 1 CM Ballantyne, 2 JJ Kastelein, 3 E Stein, 4 JL Isaacsohn,
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationMARINE Study Results
TM MARINE Study Results Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements, including those relating to the Company s product development
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationLeaders in Managing Lipids for Improved Cardiovascular Health
Leaders in Managing Lipids for Improved Cardiovascular Health INVESTOR PRESENTATION June 2015 Nasdaq: AMRN Forward-Looking Statement and Disclaimer This presentation contains forward-looking statements,
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationOmega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM
Omega-3 Fatty Acids Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Chattanooga @a_l_bailey Disclosures None Objectives Describe omega-3 fatty acids Review the historic
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationTitle :Current & Future Triglyceride Pharmaceuticals
August 23, 2014 Title :Current & Future Triglyceride Pharmaceuticals Harold Bays MD, FTOS, FACC, FACE, FNLA L-MARC Research Center Louisville, KY Disclosures: In the past 12 months, Dr. Harold Bays has
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationTriglyceride as Vascular Risk Factor
Curriculum Vitae Name : Prof. Dr. dr. Idrus Alwi SpPD, KKV, FINASIM, FACP, FACC, FESC, FAPSIC Current Position : - President of the Indonesian Society of Internal Medicine Medical Student : Faculty of
More informationInsulin resistance: targeting dyslipidemia beyond the LDL-cholesterol. Disclosures: Presentation outline
Insulin resistance: targeting dyslipidemia beyond the LDL-cholesterol Rocky Mountain Metabolic Syndrome Symposium May 14 th 21 Mori Krantz MD FACC Associate Professor, University of Colorado Director of
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationPresenter Disclosure Information
1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships
More informationKathy What Is the Risk of Low HDL-C?
Targeting Better Cardiac Outcomes for High Risk Patients Daniel Soffer, MD, FNLA Clinical Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA sofferd@uphs.upenn.edu
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationIl rischio residuo nella persona con diabete: come individuarlo e come trattarlo?
Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo? Alberto Zambon University of Padova - Italy DISCLOSURE - CONFLICT OF INTEREST Prof. A. Zambon reports having received grants,
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationControversies in Lipid Therapy: Is there any value in adjusting HDL levels?
Controversies in Lipid Therapy: Is there any value in adjusting HDL levels? Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine and Professor of Medicine, Pathology, Immunology,
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationNext Generation Lipid Modification in Cardiovascular Disease
TM Next Generation Lipid Modification in Cardiovascular Disease Investor Presentation Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements,
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationOmega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA
Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA Structure of Omega-3 and Omega-6 Fatty Acids Omega-6 fatty acids CH 3 Omega-3 fatty
More information